Amisulpride: a Brief Review.
Loading...
Date
2007-10
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Amisulpride, belonging to second generation antipsychotics, is a substituted benzamide
derivative indicated for the treatment of acute and chronic schizophrenia with prominent
positive and/or negative symptoms. Amisulpride has high affinity for the dopamine D2/D3
receptors. It inhibits dopamine transmission by blocking postsynaptic D2/D3 receptors in
the limbic system, which is predicative of potent antipsychotic activity. The elimination
half-life is 12 hours. Metabolism is limited with most of the drug excreted unchanged in
the feces (64%). Clinical studies have supported that Amisulpride (400-1200mg/day) is at
least as effective as Haloperidol and Risperidone and more effective than flupenthixol in
acute exacerbation. In the treatment of patients with predominantly negative symptoms,
Amisulpride was more effective than placebo. Recently some studies have shown it to be
having efficacy in dysthymia also. Its favorable characteristics also include low incidence
of EPSE and weight gain, however, it has a high incidence of prolactin elevation.
Description
Keywords
Citation
Chhabra Vishal, Bhatia Manjeet Singh. Amisulpride: a Brief Review. Delhi Psychiatry Journal. 2007 Oct; 10 (2): 140-143.